查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1948502

单细胞RNA定序服务市场（依最终使用者、应用、技术、工作流程阶段及细胞类型划分），2026-2032年全球预测

Single Cell RNA Sequencing Service Market by End User, Application, Technology, Workflow Stage, Cell Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，单细胞 RNA定序服务市场规模将达到 31.4 亿美元，到 2026 年将成长至 34.7 亿美元。预计到 2032 年，该市场规模将达到 72.4 亿美元，复合年增长率为 12.65%。

关键市场统计数据
基准年 2025 31.4亿美元
预计年份：2026年 34.7亿美元
预测年份 2032 72.4亿美元
复合年增长率 (%) 12.65%

策略指引：单细胞RNA定序说明将重塑生命科学领域的研究重点、营运投资与共同研究模式

单细胞RNA定序已从一项小众技术发展成为揭示研究和临床环境中细胞异质性的基础方法。随着技术的日趋成熟，实验室和公司正从群体层级分析转向单细胞层级分析，以发现罕见的细胞状态、表征微环境并绘製发育过程图谱。这种转变不仅仅是技术的进步，它正在重新定义实验设计、资源分配和跨学科合作。

全面概述单细胞RNA定序的实用性和应用情况，以及技术、营运和用户主导的变革如何推动其发展。

单细胞RNA定序领域正经历变革性的转变，这主要得益于技术创新、应用领域的拓展以及顾客期望的改变。基于液滴的系统、微流体和微孔阵列的进步提高了定序通量，同时降低了单一细胞的定序成本，从而能够实现更大规模、更复杂的实验设计。同时，样品製备和定序化学方法的改进提高了定序灵敏度和转录本覆盖率，增强了单细胞数据的可重复性和生物学洞察力。

分析近期关税政策变化对单细胞RNA定序相关人员的采购、供应商多元化和营运风险管理的影响

近期贸易政策和关税的变化给依赖全球供应链获取单细胞RNA定序所需设备、试剂和耗材的机构带来了新的挑战。关税调整会影响硬体和关键试剂的到岸成本，进而影响筹资策略、供应商选择和库存计画。因此，各机构正在重新评估其采购模式，并探索其他方案以降低关税波动带来的风险。

将最终使用者画像、科学应用、技术模式、工作流程优先顺序和细胞类型特定需求与策略决策连结起来的详细細項分析

了解细分市场对于设计满足不同终端使用者对单细胞RNA定序需求的产品和服务至关重要。学术研究机构通常优先考虑通讯协定的柔软性、高度的调查方法定制化以及获取尖端设备以进行假设驱动的发现。合约研究组织（CRO）重视通量、可重复性和可跨多个客户计划部署的标准化工作流程。医院和诊所则关注临床有效性、法规遵从性以及符合临床实验室实践的精简的「检体到结果」流程。製药和生物技术公司需要与药物研发流程整合、强大的品管以及支援下游转化研究的数据输出。

区域趋势和基础设施状况正在影响美洲、欧洲、中东和非洲以及亚太地区的部署模式、合作模式和服务覆盖范围。

区域趋势将对单细胞RNA定序技术的开发、应用和商业化产生重大影响。在美洲，学术机构、生物技术公司和临床研究中心的强大实力促进了方法学的快速创新和高通量平台的早期应用。这种环境支持设备供应商和服务实验室之间的积极合作，强调连接药物发现和临床检验的转化研究。

竞争格局评估揭示了产品整合、策略联盟和服务差异化将如何决定单细胞RNA定序的领导地位。

单细胞RNA定序领域的竞争格局呈现出平台专家、试剂开发商、服务供应商以及硬体、软体和耗材整合商并存的局面。那些能够提供端到端解决方案的公司，例如将经过检验的样品製备盒与无缝仪器整合以及强大的数据分析流程相结合，将占据市场主导地位，从而满足客户对承包工作流程的需求。同时，那些提供高度专业化的化学试剂、捕获方法或仪器的利基供应商，透过满足通用平台无法解决的特定科研需求，依然保持着市场竞争力。

领导者可以采取哪些策略步骤来扩大能力、增强韧性并加速单细胞RNA定序的转化应用

产业领导者应采取务实且多管齐下的策略，充分利用单细胞RNA定序带来的机会，同时降低营运和市场风险。首先，应有选择地投资于自动化和标准化的样品製备流程，以降低变异性并提高各类研究的通量。自动化不仅能提高可重复性，还能使技术人员专注于实验设计和结果解读，进而加快发现和转换计划的进程。

结合专家访谈、文献综述和迭代检验的稳健混合方法研究途径，能够得出关于单细胞RNA定序的可靠且可操作的结论。

本研究采用的评估单细胞RNA定序趋势的调查方法融合了定性和定量技术，以确保获得可靠且可操作的洞见。主要研究包括对来自学术实验室、受託研究机构（CRO）、临床实验室和企业研发团队的相关人员进行结构化访谈，以收集关于技术应用、工作流程挑战和供应商选择标准的多元观点。此外，我们也与方法学家、生物资讯学家和转化研究人员进行专家咨询，以检验技术假设并解读新兴趋势。

一份权威的综合报告，重点阐述了实现单细胞RNA定序全部潜力所需的战略要务、运营重点和合作途径。

单细胞RNA定序技术处于科学创新与营运演进的交汇点，它以前所未有的分辨率推动生物学发现，同时也对工作流程、基础设施和伙伴关係关係提出了新的要求。这项技术的成熟正在推动其从探索性研究向可重复、扩充性的应用转型，从而支持药物研发、转化研究和新兴的临床应用。要取得成功，各机构必须将自身的科学研究目标与在自动化、资料基础设施和供应商韧性方面的实际投资结合。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依最终用户分類的单细胞RNA定序服务市场

  • 学术和研究机构
  • CRO（受託研究机构）
  • 医院和诊所
  • 製药和生物技术公司

9. 单细胞RNA定序服务市场（依应用领域划分）

  • 癌症研究
  • 发育生物学
  • 药物发现与开发
  • 免疫学/感染疾病

10. 单细胞RNA定序服务市场（依技术划分）

  • 基于Droplet的平台
  • 基于微流体的平台
  • 基于微孔的平台

11. 依工作流程阶段分類的单细胞RNA定序服务市场

  • 数据分析
  • 样品製备
  • 定序和检测

12. 依细胞类型分類的单细胞RNA定序服务市场

  • 动物
  • 人类
  • 微生物
  • 植物

13. 按地区分類的单细胞RNA定序服务市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 按组别分類的单细胞RNA定序服务市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国单细胞RNA定序服务市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国单细胞RNA定序服务市场

第十七章：中国单细胞RNA定序服务市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Azenta Life Sciences
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • CD Genomics
  • Creative Biogene
  • Danaher Corporation
  • Dolomite Bio
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Fluent BioSciences
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • LC Sciences
  • Macrogen, Inc.
  • Mission Bio, Inc.
  • NanoString Technologies, Inc.
  • Novogene Co., Ltd.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • Parse Biosciences, Inc.
  • QIAGEN NV
  • Standard BioTools Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific Inc
Product Code: MRR-4F7A6D4FB7CF

The Single Cell RNA Sequencing Service Market was valued at USD 3.14 billion in 2025 and is projected to grow to USD 3.47 billion in 2026, with a CAGR of 12.65%, reaching USD 7.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.14 billion
Estimated Year [2026] USD 3.47 billion
Forecast Year [2032] USD 7.24 billion
CAGR (%) 12.65%

Strategic primer explaining why single cell RNA sequencing is reshaping research priorities, operational investments, and collaborative models across life sciences

Single cell RNA sequencing has evolved from a niche capability into a foundational approach for resolving cellular heterogeneity across research and clinical settings. As technologies mature, laboratories and companies are transitioning from bulk population-level assays to single cell resolution to uncover rare cell states, characterize microenvironments, and map developmental trajectories. This shift is not merely technical; it redefines experimental design, resource allocation, and cross-disciplinary collaboration.

Leaders must understand both the scientific opportunities and the operational shifts required to adopt single cell approaches at scale. Scientific teams benefit from higher-resolution data that can elucidate disease mechanisms, refine therapeutic targets, and improve biomarker discovery. Operationally, the demands on sequencing infrastructure, sample preparation workflows, and bioinformatics capacity increase, necessitating new investments and partnerships. Strategic alignment across R&D, clinical operations, procurement, and informatics is therefore essential to convert single cell insights into translational outcomes.

Moreover, cross-sector collaboration is accelerating innovation. Academic groups, clinical centers, and industry partners converge around shared data standards, interoperable pipelines, and joint validation studies. In the near term, the organizations that succeed will be those that integrate single cell methods into end-to-end workflows, balance internal capabilities with external collaborations, and prioritize reproducibility and data governance to support regulatory and translational objectives.

Comprehensive overview of the technological, operational, and user-driven transformations accelerating adoption and practical utility of single cell RNA sequencing

The landscape of single cell RNA sequencing is experiencing transformative shifts driven by technological innovation, evolving applications, and changing customer expectations. Advances in droplet-based systems, microfluidics, and microwell arrays have increased throughput while reducing per-cell costs, enabling larger and more complex experimental designs. Simultaneously, improvements in library preparation chemistries and sequencing chemistries have enhanced sensitivity and transcript coverage, making single cell data more reproducible and biologically informative.

Equally consequential is the rise of integrated workflows that bridge wet-lab processes with robust computational pipelines. As data analysis platforms mature, laboratories are moving from bespoke bioinformatics scripts toward standardized, validated solutions that facilitate cross-study comparisons and reproducibility. This maturation lowers the barrier for non-specialist users to adopt single cell techniques and accelerates their use in drug discovery, translational research, and clinical research applications.

Lastly, market dynamics reflect shifting priorities among users. Academic and research institutes prioritize methodological innovation and exploratory studies, while contract research organizations and industry partners emphasize scalable, validated workflows and regulatory compliance. Hospitals and clinics increasingly evaluate single cell approaches for diagnostic and prognostic use cases, prompting investments in clinical-grade workflows and quality management systems. These converging trends are redefining programmatic priorities and creating a more diverse ecosystem of tool providers, service vendors, and platform integrators.

Analysis of how recent tariff dynamics influence procurement, supplier diversification, and operational risk management for single cell RNA sequencing stakeholders

Recent changes in trade policy and tariff schedules have introduced new complexities for organizations that rely on global supply chains for instruments, reagents, and consumables required for single cell RNA sequencing. Tariff adjustments affect the landed cost of hardware and critical reagents, which in turn influences procurement strategies, vendor selection, and inventory planning. As a result, organizations are reassessing sourcing models and exploring alternatives to mitigate exposure to tariff volatility.

In response, many stakeholders are diversifying their supplier ecosystems to include local manufacturers, regional distributors, and vertically integrated vendors that offer end-to-end solutions. This diversification reduces reliance on any single supply route and can shorten lead times for critical reagents and consumables. Additionally, some laboratories and service providers are adopting longer-term procurement contracts and building buffer inventories to stabilize operations when tariff-driven price changes create procurement friction.

Trade policy shifts also catalyze strategic adjustments beyond sourcing. Product design and packaging choices are being reconsidered to optimize customs classifications and minimize tariff impact. Companies are increasing collaboration with logistics partners and customs experts to navigate classification disputes and maximize duty optimization. Over time, persistent tariff uncertainty can encourage nearshoring of manufacturing and assembly operations, promote local partnerships, and accelerate efforts to develop alternative reagent chemistries and platforms that are less sensitive to global tariff fluctuations. For organizations planning multi-year programs, incorporating tariff scenario planning into capital and operating budgets has become a prudent risk management practice.

In-depth segmentation analysis linking end-user profiles, scientific applications, technology modalities, workflow priorities, and cell-type specific requirements to strategic decision making

Understanding segmentation is central to designing products and services that meet diverse end-user requirements in single cell RNA sequencing. Academic and research institutes often prioritize methodological flexibility, advanced protocol customizability, and access to cutting-edge instrumentation for hypothesis-driven discovery. Contract research organizations emphasize throughput, reproducibility, and standardized workflows that can be deployed across multiple client projects. Hospitals and clinics focus on clinical validity, regulatory compliance, and streamlined sample-to-answer pathways that fit within clinical laboratory operations. Pharmaceutical and biotech companies demand integration with drug discovery pipelines, robust quality controls, and data outputs that support downstream translational work.

Application-driven needs further refine technology selection and service models. Cancer research teams require high-resolution detection of tumor heterogeneity and immune microenvironments, while developmental biology projects seek sensitive temporal profiling of differentiation states. Drug discovery and development programs value reliable cell-type resolution and scalable workflows for screening and target validation, whereas immunology and infectious disease studies emphasize single cell immune profiling and pathogen-responsive host signatures. These application nuances influence preferences for droplet-based platforms that offer high throughput, microfluidics-based systems that balance throughput with custom capture modalities, and microwell-based platforms that provide precise cell handling for specialized protocols.

Workflow stage segmentation shapes investment priorities. Laboratories allocating resources to data analysis invest in computational infrastructure, standardized pipelines, and skilled bioinformaticians. Those focused on library preparation emphasize reproducible chemistries, automation, and reagent quality control. Organizations prioritizing sequencing and detection invest in high-throughput sequencers and validated detection chemistries. Finally, cell type considerations-animal, human, microbial, and plant-introduce distinct sample preparation challenges and protocol optimizations, prompting suppliers and service providers to offer tailored kits and validated workflows to meet these biological differences.

Regional dynamics and infrastructure considerations influencing adoption patterns, collaboration models, and service footprints across Americas, EMEA, and Asia-Pacific landscapes

Regional dynamics exert a powerful influence on where and how single cell RNA sequencing capabilities are developed, adopted, and commercialized. In the Americas, a strong presence of academic institutions, biotech firms, and clinical research centers fosters rapid methodological innovation and early adoption of high-throughput platforms. This environment supports vibrant partnerships between instrument vendors and service laboratories, with an emphasis on translational research that bridges discovery and clinical validation.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory frameworks, research funding models, and healthcare infrastructure vary significantly. Established research hubs and clinical networks promote collaborative consortia and standardized protocols, while emerging markets prioritize capacity building and technology transfer. Cross-border collaborations and pan-regional initiatives are increasingly important for harmonizing data standards and scaling multicenter studies that leverage single cell approaches.

Asia-Pacific continues to expand its research and commercial capabilities, driven by growing investment in life sciences research, local manufacturing capacity, and a large, diverse patient population that enables expansive translational studies. Regional manufacturers and distributors play a pivotal role in improving accessibility to instruments and consumables, and strategic public-private partnerships are advancing clinical applications. Taken together, these regional environments influence procurement cycles, partnership models, and where service providers locate facilities to best serve multinational clients.

Competitive landscape evaluation revealing how product integration, strategic partnerships, and service differentiation determine leadership in single cell RNA sequencing

The competitive landscape in single cell RNA sequencing is characterized by a mix of platform specialists, reagent innovators, service providers, and integrators that combine hardware with software and consumables. Companies that differentiate through end-to-end solutions-pairing validated library preparation kits with seamless instrument integration and robust data analysis pipelines-are positioned to capture demand from customers seeking turnkey workflows. Meanwhile, niche vendors that offer highly specialized chemistries, capture modalities, or instrumentation maintain relevance by addressing specific scientific needs that generalist platforms cannot.

Strategic partnerships and alliances are common as companies seek to broaden their value propositions. Collaborations between instrument manufacturers and bioinformatics providers enable more intuitive data-to-insight pathways, while ties between reagent developers and clinical laboratories help accelerate validation for diagnostic workflows. Additionally, aftermarket services such as training, protocol optimization, and technical support have become important differentiators; organizations that invest in comprehensive customer enablement reduce onboarding friction and increase long-term customer retention.

Consolidation activity and selective vertical integration are also shaping competitive dynamics. Some vendors are expanding their portfolios through acquisitions or internal development to cover multiple workflow stages, thereby simplifying procurement for customers. At the same time, specialized contract research organizations and service labs carve out growth by offering flexible study execution, regulatory experience, and scaled sequencing capacity. Ultimately, the most resilient companies will balance innovation with customer-centric service and clear pathways for integration into diverse research and clinical environments.

Actionable strategic initiatives that leaders can implement to scale capabilities, enhance resilience, and accelerate translational impact in single cell RNA sequencing

Industry leaders should adopt a pragmatic, multi-dimensional strategy to capitalize on the opportunities in single cell RNA sequencing while mitigating operational and market risks. First, invest selectively in automation and standardized library preparation workflows to reduce variability and increase throughput across study types. Automation will not only enhance reproducibility but also free technical staff to focus on experimental design and interpretation, accelerating the pace of discovery and translational projects.

Second, strengthen data infrastructure and analytics capabilities. Building modular, validated pipelines that support reproducible processing, robust quality control, and interoperable data formats will increase the utility of single cell datasets. Leaders should also prioritize hiring and training bioinformatics personnel and consider partnerships with specialized analytics providers to augment internal capabilities.

Third, diversify supplier relationships and consider regional sourcing strategies that reduce exposure to tariff fluctuations and logistical disruptions. Establishing contingency inventory plans and engaging with legal and customs experts to optimize procurement contracts will provide operational resilience. Fourth, pursue collaborative validation projects with clinical and academic partners to establish credibility for clinical applications and to accelerate regulatory acceptance. Finally, maintain a continuous monitoring program for emerging technologies and regulatory guidance to ensure that investments remain aligned with scientific advances and market expectations.

Robust mixed-methods research approach combining expert interviews, literature synthesis, and iterative validation to produce reliable and actionable insights on single cell RNA sequencing

The research methodology employed for assessing single cell RNA sequencing dynamics integrates qualitative and quantitative techniques to ensure robust, actionable insights. Primary research includes structured interviews with key stakeholders across academic labs, contract research organizations, clinical laboratories, and industry R&D teams to capture diverse perspectives on technology adoption, workflow challenges, and vendor selection criteria. These interviews are complemented by expert consultations with methodological specialists, bioinformaticians, and translational scientists to validate technical assumptions and interpret emerging trends.

Secondary research synthesizes peer-reviewed literature, regulatory guidance, patent filings, and public company disclosures to contextualize technological progress and commercialization pathways. Data triangulation techniques reconcile information from multiple sources to reduce bias and increase confidence in thematic conclusions. Throughout the process, findings undergo iterative validation through follow-up interviews and targeted case reviews to ensure practical relevance and to surface operational constraints that influence real-world adoption.

Confidentiality and methodological rigor underpin the work. Interview protocols include standardized questionnaires and scoring rubrics to enable consistent cross-entity comparisons. Analytical frameworks cover technology readiness, workflow integration complexity, and strategic fit, and they are applied uniformly to enable comparative insights. This mixed-methods approach yields a nuanced understanding of capability gaps, adoption drivers, and practical levers for scaling single cell RNA sequencing initiatives.

Conclusive synthesis emphasizing the strategic imperatives, operational priorities, and collaborative pathways necessary to realize the full potential of single cell RNA sequencing

Single cell RNA sequencing stands at the intersection of scientific innovation and operational evolution, offering unprecedented resolution for biological discovery while imposing new demands on workflows, infrastructure, and partnerships. The technology's maturation is catalyzing a shift from exploratory studies to reproducible, scalable applications that support drug discovery, translational research, and emerging clinical use cases. Success will require organizations to align scientific ambition with practical investments in automation, data infrastructure, and supplier resilience.

Looking ahead, the organizations that gain sustained advantage will be those that integrate robust computational pipelines with validated wet-lab workflows, cultivate collaborative partnerships across sectors, and proactively manage supply chain and regulatory uncertainties. By prioritizing reproducibility, interoperability, and customer enablement, stakeholders can accelerate the translation of single cell insights into impactful discoveries and clinical advances. The current moment presents an opportunity for strategic investment that can yield durable scientific and operational returns when approached with rigor and foresight.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Single Cell RNA Sequencing Service Market, by End User

  • 8.1. Academic & Research Institutes
  • 8.2. Contract Research Organizations
  • 8.3. Hospitals & Clinics
  • 8.4. Pharmaceutical & Biotech Companies

9. Single Cell RNA Sequencing Service Market, by Application

  • 9.1. Cancer Research
  • 9.2. Developmental Biology
  • 9.3. Drug Discovery & Development
  • 9.4. Immunology & Infectious Disease

10. Single Cell RNA Sequencing Service Market, by Technology

  • 10.1. Droplet-Based Platforms
  • 10.2. Microfluidics-Based Platforms
  • 10.3. Microwell-Based Platforms

11. Single Cell RNA Sequencing Service Market, by Workflow Stage

  • 11.1. Data Analysis
  • 11.2. Library Preparation
  • 11.3. Sequencing & Detection

12. Single Cell RNA Sequencing Service Market, by Cell Type

  • 12.1. Animal
  • 12.2. Human
  • 12.3. Microbial
  • 12.4. Plant

13. Single Cell RNA Sequencing Service Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Single Cell RNA Sequencing Service Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Single Cell RNA Sequencing Service Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Single Cell RNA Sequencing Service Market

17. China Single Cell RNA Sequencing Service Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 10x Genomics, Inc.
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Azenta Life Sciences
  • 18.8. Becton, Dickinson and Company
  • 18.9. BGI Genomics Co., Ltd.
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. CD Genomics
  • 18.12. Creative Biogene
  • 18.13. Danaher Corporation
  • 18.14. Dolomite Bio
  • 18.15. Eurofins Scientific SE
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Fluent BioSciences
  • 18.18. Fulgent Genetics, Inc.
  • 18.19. Illumina, Inc.
  • 18.20. LC Sciences
  • 18.21. Macrogen, Inc.
  • 18.22. Mission Bio, Inc.
  • 18.23. NanoString Technologies, Inc.
  • 18.24. Novogene Co., Ltd.
  • 18.25. Oxford Nanopore Technologies plc
  • 18.26. Pacific Biosciences of California, Inc.
  • 18.27. Parse Biosciences, Inc.
  • 18.28. QIAGEN N.V.
  • 18.29. Standard BioTools Inc.
  • 18.30. Takara Bio, Inc.
  • 18.31. Thermo Fisher Scientific Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CANCER RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CANCER RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CANCER RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DEVELOPMENTAL BIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DEVELOPMENTAL BIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY IMMUNOLOGY & INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY IMMUNOLOGY & INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY IMMUNOLOGY & INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DROPLET-BASED PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DROPLET-BASED PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DROPLET-BASED PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROFLUIDICS-BASED PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROFLUIDICS-BASED PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROFLUIDICS-BASED PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROWELL-BASED PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROWELL-BASED PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROWELL-BASED PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY SEQUENCING & DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY SEQUENCING & DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY SEQUENCING & DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY ANIMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY ANIMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY ANIMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY PLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY PLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY PLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GCC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GCC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. GCC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. G7 SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. G7 SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. NATO SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA SINGLE CELL RNA SEQUENCING SERVICE MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)